Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATRC-101 + pegylated liposomal doxorubicin
- Development stage
- Discontinued
- Lead developer
- Atreca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ATRC-101 + pegylated liposomal doxorubicin is a combination therapy under clinical investigation for advanced solid malignancies. ATRC-101 is an engineered fully human IgG1 monoclonal antibody that targets a tumor-specific ribonucleoprotein (RNP) complex. It is designed to elicit anti-tumor immunity via both innate and adaptive immune responses. Pegylated liposomal doxorubicin is a reformulation of the chemotherapeutic anthracycline doxorubicin, encapsulated in pegylated liposomes to increase tumor delivery and reduce systemic toxicity; it exerts its effects mainly by inhibiting topoisomerase 2, thereby blocking DNA replication and cell division. The combination is being evaluated for potential synergistic anti-tumor activity in clinical trials, particularly in a range of solid tumors including breast, ovarian, colorectal, non-small cell lung, melanoma, head and neck, and others[1][2][4][6][8].
- Other names
- Doxil
02
Targets
DNATOP2A (DNA topoisomerase II)Tumor-specific extracellular ribonucleoprotein complex
Beyond the preview
Go deeper on ATRC-101 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATRC-101 + pegylated liposomal doxorubicin.